What's new in psoriasis? Analysis of the clinical significance of systematic reviews on psoriasis published in 2007 and 2008

Clinical and Experimental Dermatology

Volumn 34, Issue 6, 2009, Pages 664-667

  Brown, B C ^a   Warren, R B ^a   Grindlay, D J C ^b   Griffiths, C E M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; FUMARIC ACID DERIVATIVE; INFLIXIMAB; PLACEBO;

ARTHRITIS; ARTICLE; BIOLOGICAL THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; COGNITIVE THERAPY; HUMANS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELF-HELP GROUPS; TREATMENT OUTCOME;

EID: 68249157203     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2009.03414.x     Document Type: Article

References (25)

1. National Library for Health Skin Disorders Specialist Library. 2008 Annual Evidence Update on Psoriasis. Available at: http://www.library.nhs.uk/ skin/viewResource.aspx?resid=295537&code=58f104355f3656fd921c093e3f90f901 (accessed 30 December 2008).
2. Ioannidis JPA. Contradicted and initially stronger effects in highly cited clinical research. J Am Med Assoc 2005 294 : 218 28.
3. Cochrane Collaboration. Glossary of Cochrane Collaboration and research terms. Available at: http://www.cochrane.org/resources/glossary.htm (accessed 30 December 2008).
4. National Library for Health Skin Disorders Specialist Library. 2008 Annual Evidence Update on Psoriasis - Methodology. Available at: http://www.library.nhs.uk/skin/Page.aspx?pagename=PSORMETH (accessed 30 December 2008).
5. Schmitt J, Zhang Z, Wozel G et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008 159 : 513 26.
6. Brimhall AK, King LN, Licciardone JC et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008 159 : 274 85.
7. Reich K, Sinclair R, Roberts G et al. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. Curr Med Res Opin 2008 24 : 1237 54.
8. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008 59 : 996 1001.
9. Huang W, Cordoro KM, Taylor SL, Feldman SR. To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis. J Am Acad Dermatol 2008 58 : 970 7.
10. Bessell A, Moss TP. Evaluating the effectiveness of psychosocial interventions for individuals with visible differences: a systematic review of the empirical literature. Body Image 2007 4 : 227 38.
11. Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008 158 : 558 66.
12. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978 157 : 238 44.
13. Griffiths CEM, Strober B, Van de Kerkhof PCM. ACCEPT trial. A phase III multicentre study comparing ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis. Poster presented at the 17th EADV Congress, Paris, 2008; FP 1336.
14. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 19 : 210 16.
15. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 2007 370 : 263 71.
16. Harrison MJ, Dixon WG, Watson KD et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-turnover necrosis factor alpha therapy. Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009 68 : 209 15.
17. Agency for Healthcare Research and Quality. Methods and Background: U.S. Preventive Services Task Force (USPSTF). Available at: http://www.ahrq.gov/ clinic/uspstmeth.htm (accessed 30 December 2008).
18. Ginsburg IH, Link BG. Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol 1989 20 : 53 63.
19. Gupta MA, Schork NJ, Gupta AK et al. Suicidal ideation in psoriasis. Int J Dermatol 1993 32 : 188 90.
20. Newell R, Marks I. Phobic nature of social difficulty in facially disfigured people. Br J Psychiatry 2000 176 : 177 81.
21. Fortune DG, Richards HL, Griffiths CEM, Main CJ. Targeting cognitive-behaviour therapy to patients' implicit model of psoriasis: results from a patient preference controlled trial. Br J Clin Psychol 2004 43 : 65 82.
22. Fortune DG, Richards HL, Kirby B et al. A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol 2002 146 : 458 65.
23. Seng TK, Nee TS. Group therapy: a useful and supportive treatment for psoriasis patients. Int J Dermatol 1997 36 : 110 12.
24. Schulte MB, Cormane RH, van DijkE, Wuite J. Group therapy of psoriasis. Duo formula group treatment (DFGT) as an example. J Am Acad Dermatol 1985 12 : 61 6.
25. Price ML, Mottahedin I, Mayo PR. Can psychotherapy help patients with psoriasis? Clin Exp Dermatol 1991 16 : 114 17.